Back to Journals » Vascular Health and Risk Management » Volume 10

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Authors Petrella R, Tremblay G, De Backer G, Gill D

Received 2 October 2013

Accepted for publication 7 November 2013

Published 29 January 2014 Volume 2014:10 Pages 63—74

DOI https://doi.org/10.2147/VHRM.S55298

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Robert J Petrella,1 Guy Tremblay,2 Guy De Backer,3 Dawn P Gill,4,5,6

On behalf of the POWER survey Study Group

1Department of Family Medicine and Cardiology, Lawson Health Research Institute, University of Western Ontario, ON, Canada; 2Centre hospitalier universitaire de Québec, Hôpital du Saint-Sacrement, Sainte-Foy, Québec, QC, Canada; 3Department of Public Health, Ghent University, Ghent, Belgium; 4Aging, Rehabilitation and Geriatric Care Research Centre, Lawson Health Research Institute, London, ON, Canada; 5School of Health Studies, Western University, London, ON, Canada; 6Department of Epidemiology, University of Washington, Seattle, WA, USA


Purpose/introduction: The Canadian Hypertension Education Program (CHEP) has identified blood pressure (BP) control as a key target for an overall reduction in cardiovascular disease risk. The POWER survey (Physicians’ Observational Work on Patient Education According to their Vascular Risk) used Framingham methodology to investigate the impact of an angiotensin-receptor-blocker-based regimen on arterial BP and total coronary heart disease (CHD) risk in a subset of patients recruited in Canada.
Methods: 309 Canadian practices screened for patients with either newly diagnosed or uncontrolled mild/moderate hypertension (sitting systolic blood pressure [SBP] >140 mmHg with diastolic blood pressure [DBP] <110 mmHg). Treatment comprised eprosartan 600 mg/day with add-on antihypertensive therapy after 1 month if required. The primary efficacy variable was change in SBP at 6 months; the secondary variable was the absolute change in the Framingham 10-year CHD risk score.
Results: 1,385 patients were identified, of whom 1,114 were included in the intention-to-treat (ITT) cohort. Thirty-eight point four percent of ITT patients were managed with monotherapy at 6 months, versus 35.2% and 13.7% with two-drug or multiple-drug therapy, respectively. SBP in the ITT cohort declined 22.4 (standard deviation [SD] 14.8) mmHg and DBP declined 10.5 (SD 10.3) mmHg during that time. The absolute mean Framingham score declined 2.1 (SD 3.1) points with significant age and sex variation (P<0.001) and differences between the various Framingham methods used.
Discussion/conclusion: Primary care physicians were able to use a strategy of BP lowering and CHD risk assessment to achieve significant reductions in BP and Framingham-assessed CHD risk. The effect size estimate of the different Framingham methods varied noticeably; reasons for those differences warrant further investigation.


Keywords: blood pressure, hypertension, angiotensin-receptor blocker, observational study


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]